https://www.selleckchem.com/pr....oducts/Idarubicin.ht
26; 95% confidence interval [CI], 0.64-8.03; p = 0.19; HR, 2.42; 95% CI, 0.68-8.61; p = 0.16) and significantly shorter overall survival than KRAS Exon2-mutant CRC (HR, 3.88; 95% CI, 0.92-16.3; p = 0.04; HR, 4.80; 95% CI, 1.14-20.2; p = 0.02). In our multicenter study, the findings elucidated the clinical and prognostic features of patients with detailed RAS/BRAF -mutant mCRC in Japan. In our multicenter study, the findings elucidated the clinical and prognostic features of patients with detailed RAS/BRAFV600E-mutant mCRC in Japan. T
Like
Comment
Share
